Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/114176
Título: | Metformin in SARS-CoV-2 infection: A hidden path - from altered inflammation to reduced mortality. A review from the literature | Autor: | Pedrosa, Ana Realista Martins, Diana Cruz Rizzo, Manfredi Silva-Nunes, José |
Palavras-chave: | Metformin; SARS-CoV-2; COVID-19; Diabetes; Mortality; Severity | Data: | Fev-2023 | Editora: | Elsevier | Título da revista, periódico, livro ou evento: | Journal of Diabetes and its Complications | Volume: | 37 | Número: | 2 | Resumo: | SARS-CoV-2 infection has been a major threat to human health and a huge challenge to Medicine. In only two years, COVID-19 affected >350 million people, causing >5.6 million deaths. Chronic inflammatory states, such as diabetes or obesity, are known risk factors for COVID-19 poorest outcomes, with higher risk for disease severity and greater mortality. Metformin remains on the first line of the management of hyperglycemia in type 2 diabetes. Through its anti-inflammatory and immunomodulatory mechanisms, metformin appears as an opportunity to control the dysregulated cytokine storm secondary to SARS-CoV-2 infection. Recent studies point towards a potential protective role of metformin in the course of COVID-19, showing that current or previous treatment with metformin associates with better outcomes. | URI: | https://hdl.handle.net/10316/114176 | ISSN: | 10568727 | DOI: | 10.1016/j.jdiacomp.2022.108391 | Direitos: | openAccess |
Aparece nas coleções: | FMUC Medicina - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Metformin in SARS-CoV-2 infection A hidden path – from altered inflammation to reduced mortality. A review from the literature.pdf | 4.46 MB | Adobe PDF | Ver/Abrir |
Visualizações de página
158
Visto em 9/out/2024
Downloads
122
Visto em 9/out/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.